Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
- DOI
- 10.1016/s1474-4422(17)30369-1
- Published
- 2017 Dec
- Container
- The Lancet. Neurology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s1474-4422-17-30369-1,
title = {Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.},
author = {Howard JF Jr and Utsugisawa K and Benatar M and Murai H and Barohn RJ and Illa I and Jacob S and Vissing J and Burns TM and Kissel JT and Muppidi S and Nowak RJ and O'Brien F and Wang JJ and Mantegazza R and REGAIN Study Group},
year = {2017},
journal = {The Lancet. Neurology},
doi = {10.1016/s1474-4422(17)30369-1},
url = {https://doi.org/10.1016/s1474-4422(17)30369-1}
}RIS
TY - JOUR TI - Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. AU - Howard JF Jr AU - Utsugisawa K AU - Benatar M AU - Murai H AU - Barohn RJ AU - Illa I AU - Jacob S AU - Vissing J AU - Burns TM AU - Kissel JT AU - Muppidi S AU - Nowak RJ AU - O'Brien F AU - Wang JJ AU - Mantegazza R AU - REGAIN Study Group PY - 2017 JO - The Lancet. Neurology DO - 10.1016/s1474-4422(17)30369-1 UR - https://doi.org/10.1016/s1474-4422(17)30369-1 ER -
APA
Jr, H. J., K, U., M, B., H, M., RJ, B., I, I., S, J., J, V., TM, B., JT, K., S, M., RJ, N., F, O., JJ, W., R, M., & Group, R. S. (2017). Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.. The Lancet. Neurology. https://doi.org/10.1016/s1474-4422(17)30369-1
Source records
- pubmed · retrieved 2026-09-27T06:24:45.334Z